2-[5-(3-nitro-phenyl)-[1,2,4]oxadiazol-3-yl]-pyridine | 5799-85-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[5-(3-nitro-phenyl)-[1,2,4]oxadiazol-3-yl]-pyridine
• 英文别名: 3-(pyridin-2-yl)-5-(3-nitrophenyl)-1,2,4-oxadiazole；2-[5-(3-nitrophenyl)[1,2,4]oxadiazol-3-yl]pyridine；3-(2-pyridyl)-5-(3-nitrophenyl)-1,2,4-oxadiazole；5-(3-Nitrophenyl)-3-(2-pyridyl)-1,2,4-oxadiazole；5-(3-nitrophenyl)-3-pyridin-2-yl-1,2,4-oxadiazole
• CAS: 5799-85-9
• 化学式: C₁₃H₈N₄O₃
• mdl: MFCD01624376
• 分子量: 268.232
• InChiKey: YYKRPCBJFTUNFZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.45±0.1 g/cm3(Predicted)
• 溶解度：
  6.4 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  间硝基苯甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-[5-(3-nitro-phenyl)-[1,2,4]oxadiazol-3-yl]-pyridine
  参考文献：
  名称：

  Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development

  摘要：

  AZD9272 and AZD6538 are two novel mGluR5 negative allosteric modulators selected for further clinical development. An initial high-throughput screening revealed leads with promising profiles, which were further optimized by minor, yet indispensable, structural modifications to bring forth these drug candidates. Advantageously, both compounds may be synthesized in as little as one step. Both are highly potent and selective for the human as well as the rat mGluR5 where they interact at the same binding site than MPEP. They are orally available, allow for long interval administration due to a high metabolic stability and long half-lives in rats and permeate the blood brain barrier to a high extent. AZD9272 has progressed into phase I clinical studies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.100

文献信息

• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• Heterocyclic compounds for treating hepatitis C virus
  申请人：Vourloumis Dionisios

  公开号：US20050075375A1

  公开（公告）日：2005-04-07

  The invention is directed to heterocyclic compounds and pharmaceutical compositions of the same for treating Hepatitis C virus.

  这项发明涉及杂环化合物和其制备的药物组合物，用于治疗丙型肝炎病毒。
• Novel oxadiazole derivatives and their medical use
  申请人：Dahl Bjarne H.

  公开号：US20090312347A1

  公开（公告）日：2009-12-17

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的噁唑烷衍生物，其被发现是尼古丁乙酰胆碱受体的调节剂。由于其药理学特性，本发明中的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩相关的疾病或疾患、内分泌疾病或疾患、神经退行性疾病或疾患、炎症、疼痛以及由于滥用化学物质而引起的戒断症状等疾病或疾患具有用处。
• NOVEL OXADIAZOLE DERIVATIVES AND THEIR MEDICAL USE
  申请人：DAHL Bjarne H.

  公开号：US20110294856A1

  公开（公告）日：2011-12-01

  This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型的噁唑啉衍生物，其被发现是乙酰胆碱受体的调节剂。由于它们的药理特性，该发明中的化合物可能有用于治疗各种与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病或紊乱、神经退行性疾病、炎症、疼痛以及由于滥用化学物质终止而引起的戒断症状相关的疾病或紊乱。
• PHARMACEUTICAL COMBINATIONS OF A NICOTINE RECEPTOR MODULATOR AND A COGNITIVE ENHANCER
  申请人：Olsen Gunnar M.

  公开号：US20100234349A1

  公开（公告）日：2010-09-16

  This invention relates to novel pharmaceutical compositions comprising therapeutically effective combination of a positive allosteric modulator of nicotine receptors; and a cognitive enhancer selected from the group consisting of a nicotine acetylcholine receptor agonist, an acetylcholine esterase inhibitor, a positive AMPA receptor modulator, an antipsychotic drug, an antidepressant drug and an anti Parkinson drug. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating cognitive disorders.

  本发明涉及一种新型药物组合物，包括治疗有效的尼古丁受体正向变构调节剂和从以下组中选择的认知增强剂：尼古丁乙酰胆碱受体激动剂、乙酰胆碱酯酶抑制剂、正向AMPA受体调节剂、抗精神病药物、抗抑郁药物和抗帕金森药物。本发明的药物组合物特别适用于对抗认知障碍。